SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

BiomarkersOctober 7, 2026

IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses

A study from the International Association for the Study of Lung Cancer (IASLC) Pathology Committee, published in the Journal of Thoracic Oncology, proposes a new diagnostic category for well-differentiated lung neuroendocrine tumours with a high mitotic rate. The authors argue that these tumours show the molecular features of carcinoids, behave worse than atypical carcinoids, and should be classified as grade 3 carcinoids/NETs instead of LCNEC.
Share

In brief

  • The IASLC Pathology Committee collected 28 resected lung tumours with carcinoid morphology and more than 10 mitoses per 2 mm², from 9 institutions in 6 countries.
  • Under the current WHO thoracic classification these tumours are called large cell neuroendocrine carcinoma (LCNEC); the committee proposes calling them grade 3 carcinoids/NETs.
  • Every case showed wild-type Rb and p53 staining, and sequencing in 9 cases found wild-type RB1 and TP53 with a tumour mutational burden of 1.3 to 3.3 mutations/Mb.
  • Ki-67 was heterogeneous in all 28 tumours, with hot spots averaging 32% and cold-spot zones between under 1% and 15%.
  • Overall and recurrence-free survival were significantly worse than in 117 typical and 52 atypical carcinoid controls (P<0.0001 for all comparisons).

Study at a glance

  • Design: International, multi-institutional pathology study by the IASLC Pathology Committee
  • Cohort: 28 lung resections from 9 institutions in 6 countries
  • Entry criteria: Carcinoid/NET morphology with more than 10 mitoses per 2 mm²
  • Mitotic count: Mean 15 per 2 mm² (range 11 to 30)
  • Ki-67: Mean hot-spot rate 32% (range 13% to 54%), heterogeneous in every case
  • Biomarkers: Rb and p53 immunohistochemistry in all cases; next-generation sequencing in 9
  • Comparators: 117 typical and 52 atypical carcinoids
  • Not reported: Median survival figures and hazard ratios for any group, in the abstract

A category the WHO classification currently assigns to LCNEC

The current WHO thoracic classification grades well-differentiated lung NETs as typical carcinoids (grade 1) and atypical carcinoids (grade 2). A tumour that keeps carcinoid morphology but exceeds 10 mitoses per 2 mm² falls outside the atypical range, and under the present rules it is diagnosed as LCNEC, a high-grade neuroendocrine carcinoma. The authors describe this approach as “a matter of growing debate”.

The question has practical weight because LCNEC is usually grouped with the poorly differentiated neuroendocrine carcinomas, which differ from carcinoids in their molecular drivers. The tumours studied here are rare: the committee members assembled 28 resected cases across nine institutions, which the authors describe as the largest cohort of such tumours to date.

Wild-type RB1 and TP53 with a carcinoid-type genome

Immunohistochemistry showed a wild-type pattern for both Rb and p53 in all 28 tumours. Loss of Rb and aberrant p53 are typical of small cell carcinoma and of a large share of LCNEC, so their absence is consistent with a carcinoid.

Next-generation sequencing was available for 9 of the 28 cases. All 9 carried wild-type RB1 and TP53, a tumour mutational burden between 1.3 and 3.3 mutations/Mb, and genomic alterations the authors describe as characteristic of lung carcinoids. Sequencing in only a third of the cohort limits how far the genomic finding can be generalised to the whole group.

Proliferation varied widely within each tumour

Mitotic counts across the cohort averaged 15 per 2 mm², with a range of 11 to 30. The mean hot-spot Ki-67 rate was 32%, ranging from 13% to 54% between tumours.

Within every individual tumour, Ki-67 was heterogeneous. Each case contained cold-spot zones with a Ki-67 rate of under 1% to 15%. This suggests that a small biopsy taken from a cold-spot zone could underestimate the grade of the tumour, a point that bears on how these cases are recognised before resection.

Shorter survival than typical and atypical carcinoids

The 28 tumours had significantly worse overall survival and recurrence-free survival than control groups of 117 typical and 52 atypical carcinoids, with P<0.0001 for every comparison. The abstract reports comparisons with lower-grade carcinoids only, and gives no comparison with conventional LCNEC or small cell carcinoma.

The cases were contributed by committee members and were not collected consecutively, which may introduce selection bias. All cases were surgical resections, so the findings describe operable disease.

“By assembling the largest cohort to-date of the study cases, we propose that they should be classified as grade 3 carcinoids/NETs rather than LCNEC to enable clinical management more aligned with their biology.”Rekhtman et al., Journal of Thoracic Oncology (2026)

A companion proposal to add Ki-67 to the grading criteria

The authors link their proposal to a concurrent IASLC proposal to include Ki-67 as an additional criterion for grade 3 carcinoids. Ki-67 would give pathologists a second criterion alongside the mitotic count, which matters for tumours whose Ki-67 varies as widely as it did in this cohort.

The authors present the work as addressing a major unresolved issue for the WHO classification. In their view, patients whose tumours are currently reported as LCNEC on the basis of mitotic count alone could then receive management more closely matched to the biology of their disease.

Sources

  1. Journal of Thoracic Oncology. Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category (2026-09-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Paul Hofman.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Nov 13 2026
ILCS 2026
Biomarkers

ctDNA-guided decisions in lung cancer: ready or not?

M. Das
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Biomarkers

Cutting-Edge Diagnostic Techniques and Emerging Biomarkers

} 24 min

M. Ilié
SCLC by Solange Peters, Giannis Mountzios, Jacob Sands
Jun 17 2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

G. MountziosJ. SandsS. Peters
Stephen Liu
Oct 04 2024
ILCS 2024
SCLC

Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies

} 25 min

S. Liu
Anne Schultheis
Oct 04 2024
ILCS 2024
Biomarkers

Advancements in Diagnostics: Current Guidelines and Emerging Tests

} 20 min

A. Schultheis
Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Articles
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 05 2026
RESEARCH
SCLCImmunotherapies

Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry

M. Hochmair
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

N. FrostM. ReckA. Cortellini
Oct 04 2026
RESEARCH
SCLCImmunotherapies

Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC

S. LiuM. ReckC. Rudin
Oct 02 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti
Sep 30 2026
RESEARCH
Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

C. Rolfo
Sep 18 2026
CONGRESS
SCLCADCs

Ris-Rez improved OS against topotecan in relapsed SCLC in China

Sep 16 2026
CONGRESS
SCLCTargeted Therapies

Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 13 2026
CONGRESS
SCLCADCs

ARTEMIS-008: risvutatug rezetecan lifts relapsed-SCLC survival to 18.5 months

Sep 13 2026
CONGRESS
SCLCADCs

Tam-Peli extends overall survival over topotecan in relapsed SCLC: TAISHAN-302

Sep 13 2026
CONGRESS
Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months